Logo: to the web site of Uppsala University

uu.sePublications from Uppsala University
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Hyperhidrosis Substantially Reduces Quality of Life in Children: A Retrospective Study Describing Symptoms, Consequences and Treatment with Botulinum Toxin
Hidrosis Clin, Warfvinges Vag 35, SE-11251 Stockholm, Sweden..
Hidrosis Clin, Warfvinges Vag 35, SE-11251 Stockholm, Sweden..
Hidrosis Clin, Warfvinges Vag 35, SE-11251 Stockholm, Sweden..
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Dermatology and Venereology. Hidrosis Clin, Warfvinges Vag 35, SE-11251 Stockholm, Sweden.
2018 (English)In: Acta Dermato-Venereologica, ISSN 0001-5555, E-ISSN 1651-2057, Vol. 98, no 1, p. 103-107Article in journal (Refereed) Published
Abstract [en]

Studies on children with hyperhidrosis are sparse. This retrospective study presents clinical data and quality of life, along with treatment effect and safety of botulinum toxin (BTX). Case reports from 366 children were included to capture the medical history of hyperhidrosis. The total median score of the Dermatology Life Quality Index before treatment was 11 for children aged 16-17 years and 12 for children younger than 16 years. The children described physical, psychosocial and consequence-related symptoms. More than 70% had multifocal hyperhidrosis. BTX-A and/or BTX-B were given to 323 children, 193 of whom received repeated treatments. The highest score in a 5-grade scale concerning treatment effect was reported by 176/193 children, i.e. their "sweating disappeared completely". No severe adverse events occurred. Focal and multifocal hyperhidrosis in children reduces quality of life considerably. Treatment with BTX-A and/or BTX-B has been performed with success.

Place, publisher, year, edition, pages
ACTA DERMATO-VENEREOLOGICA , 2018. Vol. 98, no 1, p. 103-107
Keywords [en]
hyperhidrosis, children, botulinum toxin, botulinum toxin type A, botulinum toxin type B, quality of life
National Category
Dermatology and Venereal Diseases
Identifiers
URN: urn:nbn:se:uu:diva-346235DOI: 10.2340/00015555-2755ISI: 000423836600017PubMedID: 28761964OAI: oai:DiVA.org:uu-346235DiVA, id: diva2:1191359
Available from: 2018-03-19 Created: 2018-03-19 Last updated: 2018-03-19Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records

Swartling, Carl

Search in DiVA

By author/editor
Swartling, Carl
By organisation
Dermatology and Venereology
In the same journal
Acta Dermato-Venereologica
Dermatology and Venereal Diseases

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 269 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf